Gerresheimer (GXI) Given a €74.00 Price Target at JPMorgan Chase & Co.
Gerresheimer (ETR:GXI) has been given a €74.00 ($91.36) target price by investment analysts at JPMorgan Chase & Co. in a research report issued on Tuesday. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.’s price objective indicates a potential upside of 10.37% from the stock’s current price.
Other analysts have also recently issued research reports about the stock. Commerzbank set a €77.00 ($95.06) price objective on shares of Gerresheimer and gave the company a “buy” rating in a research report on Monday, February 5th. Hauck & Aufhaeuser set a €55.00 ($67.90) price objective on shares of Gerresheimer and gave the company a “sell” rating in a research report on Tuesday, February 6th. Independent Research set a €74.00 ($91.36) price objective on shares of Gerresheimer and gave the company a “neutral” rating in a research report on Thursday, January 25th. Goldman Sachs set a €68.00 ($83.95) price objective on shares of Gerresheimer and gave the company a “neutral” rating in a research report on Thursday, January 25th. Finally, Berenberg Bank set a €78.00 ($96.30) price objective on shares of Gerresheimer and gave the company a “buy” rating in a research report on Friday, March 9th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. Gerresheimer presently has an average rating of “Hold” and an average price target of €69.64 ($85.97).
Shares of Gerresheimer (GXI) opened at €67.05 ($82.78) on Tuesday. The firm has a market cap of $2,100.00 and a price-to-earnings ratio of 20.89. Gerresheimer has a 52-week low of €59.97 ($74.04) and a 52-week high of €78.25 ($96.60).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.